Back to search
FDAFDA · Food and drugs·Recall number D-0107-2018

Isradapine Capsules USP 2.5 mg, 100-count bottles, Rx only, Manufactured by: Elite Laboratories, Inc. Northvale, NJ 07647, NDC 42806-263-01, UPC 342806263013

Published December 13, 2017 · Recall initiated: November 13, 2017

Summary

FDA records drug Class III recall D-0107-2018, published December 13, 2017 and initiated November 13, 2017. Recalling firm: Elite Laboratories Inc.; Status: Terminated; Reported quantity: 1264 bottles; Lot: Lot #: P0910-017, Exp. 05/2019. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Elite Laboratories Inc.
Distributor
NY only
UPC
342806263013
Lot
Lot #: P0910-017, Exp. 05/2019
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Isradapine Capsules USP 2.5 mg, 100-count bottles, Rx only, Manufactured by: Elite Laboratories, Inc. Northvale, NJ 07647, NDC 42806-263-01, UPC 342806263013 recalled?

Yes. FDA published recall D-0107-2018 on December 13, 2017. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail

How do I know if my unit is part of the recall?

Compare your product details with the notice. UPC: 342806263013.